Dr. Huo’s research interests focus on the genetic, molecular, and environmental factors underlying etiology, prognosis, and treatment of cancers, particularly as they relate to cancer in underserved populations. His research spans across several areas of cancer epidemiology and clinical epidemiology, including:
1. Genetic epidemiology of breast cancer, particular in women of African ancestry with the use of genome-wide association and whole genome sequencing approach.
2. Environmental and lifestyle factors for breast cancer etiology in African women and risk prediction model building, and strategy for cancer screening.
3. Health disparity in breast cancer outcomes in multiethnic patient cohort study with multi-dimensional data.
4. Investigation of the utilization and effectiveness of cancer treatment in real world using Big data.
5. Prenatal exposure to diethylstilbestrol and clear cell adenocarcinoma of vagina and cervix, as well as other health conditions in later life.
6. Epigenetics and non-coding RNAs, such as microRNAs in relationship to cancer prognosis and survival.
Erratum: Feasibility of cancer genetic counselling and screening in Cameroon: perceived benefits and barriers.
Erratum: Feasibility of cancer genetic counselling and screening in Cameroon: perceived benefits and barriers. Ecancermedicalscience. 2023; 17:1604.
PMID: 37799949
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis.
Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. Telemed J E Health. 2023 Sep 07.
PMID: 37676974
Benign breast disease and breast cancer risk in African women: A case-control study.
Benign breast disease and breast cancer risk in African women: A case-control study. Res Sq. 2023 Sep 01.
PMID: 37693385
Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores-Reply.
Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores-Reply. JAMA Oncol. 2023 09 01; 9(9):1299-1300.
PMID: 37498624
Feasibility of cancer genetic counselling and screening in Cameroon: perceived benefits and barriers.
Feasibility of cancer genetic counselling and screening in Cameroon: perceived benefits and barriers. Ecancermedicalscience. 2023; 17:1588.
PMID: 37799957
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort.
Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. Res Sq. 2023 Aug 10.
PMID: 37609132
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
PMID: 37231433
A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes.
A joint transcriptome-wide association study across multiple tissues identifies candidate breast cancer susceptibility genes. Am J Hum Genet. 2023 06 01; 110(6):950-962.
PMID: 37164006
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients.
Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. NPJ Breast Cancer. 2023 May 06; 9(1):33.
PMID: 37149628
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer.
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. Breast Cancer Res Treat. 2023 Jul; 200(1):75-83.
PMID: 37120458
Study section of P01
NIH/NCI
2019
Study section of R01/R21
NIH/NCI
2018 - 2023
Study section of U01, H3Africa
NIH/NHGRI
2017
Study section of P01
NIH/NCI
2017
Runner-up in the Up For A Challenge – Stimulating Innovation in Breast Cancer Genetic Epidemiology
National Cancer Institute
2016
Study section of U54
NIH/NIMHD
2015
Distinguished Investigator Junior Award
University of Chicago
2014
Breast Cancer Research Program study section
U.S. Army Medical Research and Materiel Command
2013 - 2014
Breast Cancer Research Program study section
U.S. Army Medical Research and Materiel Command
2010
Breast Cancer Research Program study section
U.S. Army Medical Research and Materiel Command
2008
Delta Omega
National Honor Society in Public Health
2005
Haenszel Award for Excellence in Research
University of Illinois at Chicago
2005
Student Travel Award
University of Illinois at Chicago
2000